TY - JOUR
T1 - Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
AU - Bogaards, Johannes A.
AU - Van Der Weele, Pascal
AU - Woestenberg, Petra J.
AU - Van Benthem, Birgit H. B.
AU - King, Audrey J.
N1 - Funding Information:
Financial support. This work was supported by the Dutch Ministry of Health, Welfare and Sport, and by the Strategic Programme from the National Institute for Public Health and the Environment, through grant number S/113005/01/PT (Prometheus project).
Publisher Copyright:
© 2019 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and -18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31, -33, -35, -45, -52, and possibly -58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or -18.
AB - To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and -18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31, -33, -35, -45, -52, and possibly -58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or -18.
KW - HPV
KW - papillomavirus
KW - phylogeny
KW - bivalent vaccine
KW - cross-protection
U2 - 10.1093/infdis/jiz280
DO - 10.1093/infdis/jiz280
M3 - Article
C2 - 31165164
SN - 0022-1899
VL - 220
SP - 1141
EP - 1146
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 7
ER -